Hepatic Pyruvate dehydrogenase kinase 4 (PDK4) levels are highly induced in human patients with NASH, whereas deletion of Pdk4 improves fatty liver in mice [89]. Here, PDK4 is linked to metabolic dysfunction-associated steatohepatitis.